Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
H. Lundbeck ASFRA:LDBA +1.72%84 Debt-to-EBITDA is 1.27 as of Mar. 2026, which is 18% below its 10-year median of 1.55. GuruFocus rates FRA:LDBA with a GF Score™ of 84/100 and a GF Value™ of €6.01 (Fairly Valued). The stock has 3 warning signs investors should review. Among 690 Drug Manufacturers companies, H. Lundbeck AS ranks worse than 55.94% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for H. Lundbeck AS's Debt-to-EBITDA or its related term are showing as below:
FRA:LDBA'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.01 Med: 1.55 Max: 2.92
Current: 2
During the past 13 years, the highest Debt-to-EBITDA Ratio of H. Lundbeck AS was 2.92. The lowest was 0.01. And the median was 1.55.
FRA:LDBA's Debt-to-EBITDA is ranked worse than 55.94% of 690
companies
in the Drug Manufacturers industry
Industry Median: 1.67
vs FRA:LDBA: 2.00
H. Lundbeck AS (FRA:LDBA) Debt-to-EBITDA Explanation
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
H. Lundbeck AS Debt-to-EBITDA Related Terms
H. Lundbeck AS Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for H. Lundbeck AS's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:LDBA vs ZTS, UTHR, VTRS: Debt-to-EBITDA Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, H. Lundbeck AS's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
H. Lundbeck AS Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, H. Lundbeck AS's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where H. Lundbeck AS's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
H. Lundbeck AS (FRA:LDBA) has a Debt-to-EBITDA of 1.27 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on H. Lundbeck AS. This is 18% below median its historical median of 1.55. Over the past decade, H. Lundbeck AS's Debt-to-EBITDA has ranged from 0.01 to 2.92. According to the industry distribution chart, H. Lundbeck AS ranks #386 out of 690 companies in the Drug Manufacturers industry, placing it in the top 55.9%.
Is H. Lundbeck AS's Debt-to-EBITDA too high?
H. Lundbeck AS's current Debt-to-EBITDA of 1.27 is 18% below median its 10-year median of 1.55. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 2.92. The Drug Manufacturers industry median Debt-to-EBITDA is 1.67. H. Lundbeck AS's value of 1.27 is 24% below this industry median. Based on the distribution chart, H. Lundbeck AS ranks #386 out of 690 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, H. Lundbeck AS has a GF Score™ of 84/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does H. Lundbeck AS's Debt-to-EBITDA compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, H. Lundbeck AS ranks #386 out of 690 companies for Debt-to-EBITDA. This places H. Lundbeck AS in the lower half of its industry. The industry median Debt-to-EBITDA is 1.67. H. Lundbeck AS's value of 1.27 is 24% below this benchmark. Historically, H. Lundbeck AS's own Debt-to-EBITDA has ranged from 0.01 to 2.92 over the past decade. While the company's 10-year median is 1.55 vs. the industry median of 1.67, H. Lundbeck AS has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.67, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. H. Lundbeck AS's current Debt-to-EBITDA of 1.27 is 24% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on H. Lundbeck AS. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.67 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. H. Lundbeck AS's current Debt-to-EBITDA is 1.27, which is 18% below median its own 10-year median of 1.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is H. Lundbeck AS stock overvalued right now?
Based on GuruFocus' analysis, H. Lundbeck AS (FRA:LDBA) is currently considered Fairly Valued. The stock's GF Value™ is €6.01, compared to a current price of €5.61 — trading 6.7% below its estimated fair value. The current Debt-to-EBITDA is 1.27, which is 18% below median its 10-year median of 1.55 and 24% below the Drug Manufacturers industry median of 1.67. H. Lundbeck AS's overall GF Score™ is 84/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For H. Lundbeck AS (FRA:LDBA), the current Debt-to-EBITDA is 1.27 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is H. Lundbeck AS (FRA:LDBA) Overvalued in 2026?
Based on GuruFocus' analysis, H. Lundbeck AS stock appears to be undervalued.
The current stock price of €5.61 is trading 6.7% below its estimated GF Value™ of €6.01.
GuruFocus considers H. Lundbeck AS to be Fairly Valued.
Key valuation signals for FRA:LDBA:
Debt-to-EBITDA: 1.27 (18% below median its 10-year median of 1.55)
GF Value™: €6.01 vs. price of €5.61 (6.7% below fair value)
Industry Position: 24% below the Drug Manufacturers median (#386 of 690)
No single metric tells the full story. See the FRA:LDBA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lundbeck is a Denmark-based pharmaceutical firm that focuses on the development and commercialization of central nervous system drugs including antidepressants, antipsychotics, and antiepileptic products. The company's portfolio includes Abilify Maintena and Rexulti for psychosis, Brintellix/Trintellix for depression, Northera for Parkinson's disease symptoms, Sabril and Onfi for seizures, and Vyepti for migraine prevention. Most of the company's sales are derived in North America, followed by Asia and Europe.
84GF Score
Get the complete analysis for FRA:LDBA
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:LDBA has been successfully added to your 
